Document is current
Any future updates will be listed below
-
Authors
Kanamori, Masakazu
Sato, Izumi https://orcid.org/0000-0002-1770-0260
Koo, Christine Xing’er
Sun, Yang
Kawauchi, Hiroki
Nakagawa, Kenji https://orcid.org/0009-0002-1894-2285
Murai, Atsuko
Asanuma, Kentaro
Gan, Siok Wan
Pang, Chai Ling
Shimizu, Yuichiro
Shida-Kawazoe, Meiri
Kanamaru, Chisako
Kayukawa, Yoko
Hada, Natsuko
Ohmine, Ken
Kitazawa, Takehisa https://orcid.org/0000-0002-4958-7936
Nezu, Junichi
Igawa, Tomoyuki https://orcid.org/0000-0003-0097-8220
Shimada, Hideaki https://orcid.org/0000-0003-4932-1385
- License Information
-
More Information
Article History
Received: 2 December 2024
Accepted: 20 January 2026
First Online: 28 January 2026
Competing interests
: M.K., I.S., H.K., K.N, A.M, K.A., Y.S 2 ., M.S.-K., C.K., Y.K., N.H., K.O., T.K., T.I., and H.S. are employees of Chugai Pharmaceutical Co. Ltd. (Chugai). Y.S 1 ., and S.W.G. are employees of Chugai’s subsidiary, Chugai Pharmabody Research Pte. Ltd.(Chugai Pharmabody Research). J.N was employees of Chugai, and C.X.K and C.L.P. were employees of Chugai Pharmabody Research at the time of the study. H.S. was a Chief Executive Officer of Chugai Pharmabody Research Pte. Ltd. M.K., I.S., H.K., K.N., A.M., K.A., Y.S 2 ., M.S.-K., C.K., Y.K., N.H., K.O., J.N., T.K., T.I., and H.S. have stock in Chugai. Chugai has filed patent applications related to the anti-latent TGF-β1 antibodies. M.K. is the inventor of the following patent: CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE (WO2019/163927). M.K., H.S., and C.X.K. are the inventors of the following patent: CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE (WO2021/039945) and USES OF CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES (WO2022/180764).
